EP3293174A1 — Crystalline salts of betrixaban
Assigned to Sandoz AG · Expires 2018-03-14 · 8y expired
What this patent protects
The present invention relates to crystalline salts of betrixaban and processes for their preparation. More specifically, it relates to crystalline betrixaban hydrochloride, crystalline betrixaban citrate and to crystalline form B of betrixaban hydrobromide. It also relates to a p…
USPTO Abstract
The present invention relates to crystalline salts of betrixaban and processes for their preparation. More specifically, it relates to crystalline betrixaban hydrochloride, crystalline betrixaban citrate and to crystalline form B of betrixaban hydrobromide. It also relates to a pharmaceutical composition comprising said crystalline salts of betrixaban and one or more pharmaceutically acceptable excipients. The invention also concerns the use of said pharmaceutical compositions as a medicament, in particular for the prevention and the treatment of disease conditions characterized by undesired thrombosis.
Drugs covered by this patent
- Bevyxxa (BETRIXABAN) · Portola Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.